Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer

Clinica Chimica Acta

Volumn 438, Issue , 2015, Pages 98-102

  Kadam, Charushila Yuvraj ^a   Abhang, Subodhini A ^a  

^a B J MEDICAL COLLEGE   (India)

Author keywords

Adjuvant chemotherapy; Apoptosis; Breast cancer; Cytochrome c; Fas ligand; Granzyme B

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME C; DOXORUBICIN; EPIRUBICIN; FAS LIGAND; FLUOROURACIL; GRANZYME B; PACLITAXEL; GRANZYME;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BREAST CANCER; CANCER STAGING; DISEASE ASSOCIATION; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; ENZYMOLOGY; MIDDLE AGED;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CYTOCHROMES C; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; GRANZYMES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84906751241     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.08.012     Document Type: Article

References (38)

1. Reimer T., Herrnring C., Koczan D., et al. FasL:Fas ratio-a prognostic factor in breast carcinoma. Cancer Res 2000, 60:822-828.
2. Debatin K.M., Krammer P.H. Death receptors in chemotherapy and cancer. Oncogene 2004, 23:2950-2966.
3. Rousalova I., Krepela E. Granzyme B induced apoptosis in cancer cells and its regulation. Int J Oncol 2010, 37:1361-1378.
4. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-288.
5. Bellone G., Smirne C., Carbone A., et al. Production and proapoptotic activity of soluble CD 95 ligand in pancreatic carcinoma. Clin Cancer Res 2000, 6:2448-2455.
6. Kozlowski M., Kowalczuk O., Sulewska A., et al. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus. Folia Histochem Cytobiol 2007, 45(3):199-204.
7. Nishigaki K., Minatoguchi S., Seishima M., Asano K., Noda T., Yasuda N. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 1997, 29:1214-1220.
8. Hohlbaum A.M., Moe S., Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000, 191(7):1209-1219.
9. Mizutani Y., Hongo F., Sato N., Ogawa O., Yoshida O., Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 2001, 92:287-293.
10. Song E., Chen J., Ouyang N., Su F., Wang M., Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001, 85(7):1047-1054.
11. Takemura Y., Fukuo K., Yasuda O., et al. Fas signaling induces Akt activation and upregulation of endothelial nitric oxide synthase expression. Hypertension 2004, 43:880-884.
12. Martins G.A., Vieira L.Q., Cunha F.Q., Silva J.S. Gamma interferon modulates CD95 (Fas) and CD95L (Fas-L) expression and nitric oxide-induced apoptosis during the acute phase of Trypanosoma cruzi infection: a possible role in immune response control. Infect Immun 1999, 67(8):3864-3871.
13. Micheau O., Solary E., Hammann A., Martin F., Dimanche-Boitrel M. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997, 89:783-789.
14. Jiang S., Moriarty-Craige S.E., Li C., et al. Associations of plasma soluble Fas ligand with aging and age related macular degeneration. Invest Ophthalmol Vis Sci 2008, 49:1345-1349.
15. Janssen O., Qian J., Linkermann A., Kabelitz D. CD 95 ligand-death factor and costimulatory molecule?. Cell Death Differ 2003, 10:1215-1225.
16. D'Eliseo D., Pisu P., Romano C., et al. Granzyme B is expressed in urothelial carcinoma and promotes cancer cell invasion. Int J Cancer 2009, 127:1283-1294.
17. Cullen S.P., Brunet M., Martin S.J. Granzymes in cancer and immunity. Cell Death Differ 2010, 17:616-623.
18. Goldbach-Mansky R., Suson S., Wesley R., Hack C.E., El-Gabalawy H., Tak P. Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis. Ann Rheum Dis 2005, 64:715-721.
19. Shah D., Kiran R., Wanchu A., Bhatnagar A. Soluble granzyme B and cytotoxic T lymphocyte activity in the pathogenesis of systemic lupus erythematosus. Cell Immunol 2011, 269:16-21.
20. Adachi N., Hirota M., Hamaguchi M., Okamoto K., Watanabe K., Endo F. Serum cytochrome c level as a prognostic indicator in patients with systemic inflammatory response syndrome. Clin Chim Acta 2004, 342:127-136.
21. Barczyk K., Kreuter M., Pryjma J., et al. Serum cytochrome c indicates in vivo apoptosis and can serve as prognostic marker during cancer therapy. Int J Cancer 2005, 116:167-173.
22. Beachy S.H., Repasky E.A. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 2008, 57:759-775.
23. Tanaka M., Suda T., Haze K., et al. Fas ligand in human serum. Nat Med 1996, 2:317-322.
24. Watchmaker P.B., Urban J.A., Berk E., et al. Memory CD8+ T cells protect dendritic cells from CTL killing. J Immunol 2008, 180(6):3857-3865.
25. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309.
26. Naumnik W., Izycki T., Ossolinska M., Chyczewska E. Serum levels of sFas and sFasL during chemotherapy of lung cancer. Exp Oncol 2007, 29(2):132-136.
27. Nolen B.M., Marks J.R., Ta'san S., et al. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 2008, 10(3):R45.
28. Kavathia N., Jain A., Walston J., Beamer B.A., Fedarko N.S. Serum markers of apoptosis decrease with age and cancer stage. Aging 2009, 1(7):652-663.
29. Bladergroen B.A., Meijer C.J.L.M., ten Berge R.L., et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood 2002, 99:232-237.
30. De Bruin P.C., Kummer J.A., van der Valk P., et al. Granzyme B expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. Blood 1994, 84(11):3785-3791.
31. Spaeny-Dekking E.H.A., Hanna W.L., Wolbink A.M., et al. Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol 1998, 160:3610-3616.
32. Boivin W.A., Cooper D.M., Hiebert P.R., Granville D.J. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 2009, 89:1195-1220.
33. Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P., Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002, 87:21-27.
34. DrugBank Cyclophosphamide (DB00531) [28/07/2014]. http://www.drugbank.ca/drugs/DB00531.
35. Thorn C.F., Oshiro C., Marsh S., et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011, 21(7):440-446.
36. DrugBank Epirubicin (DB00445) [28/07/2014]. http://www.drugbank.ca/drugs/DB00445.
37. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanism of action and clinical strategies. Nat Rev Cancer 2003, 3(5):330-338.
38. DrugBank Paclitaxel (DB01229) [20/07/2014]. http://www.drugbank.ca/drugs/DB01229.